Jude Onyia - 29 Nov 2025 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Scientific Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Issuer symbol
NBIX
Transactions as of
29 Nov 2025
Net transactions value
-$342,056
Form type
4
Filing time
02 Dec 2025, 17:14:58 UTC
Previous filing
04 Sep 2025
Next filing
03 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Onyia Jude Chief Scientific Officer 6027 EDGEWOOD BEND CT., SAN DIEGO /s/ Darin Lippoldt, Attorney-in-Fact 02 Dec 2025 0001894425

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $0 +4,426 +32% $0.000000 18,129 29 Nov 2025 Direct
transaction NBIX Common Stock Tax liability $342,056 -2,248 -12% $152.16 15,881 29 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Restricted Stock Unit Options Exercise $0 -4,426 -100% $0.000000 0 29 Nov 2025 Common Stock 4,426 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by Neurocrine Biosciences, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.
F2 Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock.
F3 This RSU was granted to the Reporting Person on November 29, 2021. In accordance with the terms of the RSU, the award vested as to 4,425 shares on November 29, 2022, vested as to 4,425 shares on November 29, 2023, vested as to 4,426 shares on November 29, 2024, and vested as to 4,426 shares on November 29, 2025, subject to the terms and conditions of the award.